Liver-specific thyroid hormone receptor β1 (THR-β1) agonists, such as resmetirom, have shown promise in preclinical and clinical studies for reducing hepatic fat and inflammation in NAFLD without systemic side effects (21). This evidence concerns the gene THRB and metabolic dysfunction-associated steatotic liver disease.